Welcome to our dedicated page for Kodiak Sciences news (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences stock.
Kodiak Sciences Inc. (Nasdaq: KOD) is a precommercial, retina-focused biotechnology company whose news flow centers on clinical trial progress, scientific data presentations and capital markets activity. The company is developing biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), built on its proprietary ABC Platform and late-stage programs tarcocimab, KSI-501 and KSI-101.
On this page, readers can follow news about Kodiak’s Phase 3 studies, including GLOW2 in diabetic retinopathy, DAYBREAK in wet age-related macular degeneration, and the PEAK and PINNACLE studies in MESI. Company press releases describe milestones such as completion of enrollment in pivotal trials, new data from the Phase 1b APEX study of KSI-101, and updates on the performance of tarcocimab and KSI-501 in retinal vascular indications.
Kodiak Sciences also issues news about participation in major scientific and investor conferences, where its management and clinical collaborators present data on retinal programs and discuss the potential of IL-6 and VEGF targeting in eye disease. In addition, investors will find announcements related to public offerings of common stock and other financing activities, which the company uses to support its late-stage development and manufacturing efforts.
For anyone tracking KOD stock or developments in retinal biotechnology, this news feed offers a centralized view of Kodiak Sciences’ clinical, scientific and corporate updates as it advances its portfolio of investigational retinal medicines.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q3 2021 results, highlighting operational progress in its pivotal clinical programs for KSI-301 targeting retinal diseases. The company anticipates topline data readouts starting in early 2022, with significant studies such as DAZZLE and BEACON scheduled. As of September 30, 2021, Kodiak holds $799.2 million in cash, but reported a net loss of $67.5 million, up from $36.1 million in Q3 2020. Total R&D expenses reached $56 million, reflecting increased clinical trial costs.
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in two virtual investor conferences. The first is the Jefferies London Healthcare Conference on November 18, where a pre-recorded fireside chat will be available at 12:00 a.m. PT. The second event is the Evercore ISI 4th Annual HealthCONx Conference on December 1, starting at 8:45 a.m. PT. Live webcasts will be accessible in the "Events and Presentations" section of Kodiak's website, with replays available following the events.
Kodiak Sciences Inc. (Nasdaq: KOD) has introduced a Long-Term Performance Incentive Plan (LTPIP) for its named executive officers and eligible employees, pending stockholder approval at an upcoming meeting in October. Participants can opt to forego up to 75% of their annual equity awards for seven years in exchange for performance-based stock options that can yield three times the value. Key milestones include stock price increases to $200 and ultimately $800 per share. Additional operational milestones involve FDA approvals and achieving over $2.5 billion in sales.
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 8:45 a.m. PT. The presentation will focus on the company's innovative therapeutics for retinal diseases. A live webcast will be accessible via the company's website and available for replay post-event. Kodiak is dedicated to advancing treatments for conditions like age-related macular degeneration and diabetic eye diseases using its proprietary ABC Platform™.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its second quarter 2021 results, highlighting significant progress in several clinical trials, including the DAZZLE and BEACON studies. The company ended Q2 with $880.9 million in cash, but reported a net loss of $55.9 million, increasing from $26.0 million a year earlier. R&D expenses rose sharply to $45.4 million due to escalating clinical trial costs. Additionally, Kodiak's IND approvals in China aim to enhance global trial participation for its KSI-301 product, with topline data expected in early 2022.
Kodiak Sciences Inc. (Nasdaq: KOD) has announced its participation in two upcoming virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference on June 3, 2021, at 1:00 PM PT, and the second is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:40 PM PT. Both presentations will be available via live webcast on the company's website, with replays offered afterward. Kodiak focuses on developing therapeutics for retinal diseases, leveraging its ABC Platform™.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q1 2021 financial results, highlighting a net loss of $50.4 million, or $0.98 per share, compared to a net loss of $24.4 million in Q1 2020. Cash and equivalents stood at $929 million. The company is making significant progress in its pivotal studies for KSI-301, with the DAZZLE study fully enrolled and the launch of the DAYLIGHT study planned for summer 2021, aiming to broaden product labeling. R&D expenses increased to $40.3 million, driven by higher clinical trial costs. G&A expenses rose to $10.2 million due to payroll increases.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on retinal diseases, will present at two upcoming virtual investor conferences. The first is the Truist Securities 2021 Life Sciences Summit on May 4 at 8:20 a.m. PT, and the second is the UBS Global Healthcare Virtual Conference on May 25 at 12:00 p.m. PT. A live webcast will be available on Kodiak's website and can be replayed for a limited time. Kodiak is known for its ABC Platform™ and lead product candidate KSI-301, targeting major retinal vascular diseases.
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in two virtual investor conferences. The Barclays Global Healthcare Conference is scheduled for March 10 at 8:30 a.m. PT, and the J.P. Morgan Napa Valley Forum will occur on March 31 at 8:00 a.m. PT. Both presentations will be available via live webcast on Kodiak's website, with replays accessible for a limited time after the events. Kodiak focuses on developing therapies for retinal diseases, leveraging its innovative ABC Platform™ to advance its product candidates, including KSI-301.
Kodiak Sciences Inc. (Nasdaq: KOD) reported Q4 2020 financial results, revealing a net loss of $46.6 million, or $0.97 per share, up from a $15.6 million loss in Q4 2019. The company's cash position improved to $969 million, boosted by a $612 million equity offering. Phase 1b data for KSI-301 showed significant treatment durability, with two-thirds of patients achieving a 6-month treatment-free interval after three doses. Kodiak is advancing its pivotal clinical studies, including DME and RVO, with key milestones expected in 2022.